active

Phase 3Small molecule

Pfizer

active is one of 176 small molecule programs targeting Common Cold. It is currently in Phase 3.

Indications

Total Trials

Active Trials

175

Competitors

Pipeline

Status by Indication[3][1]

Indication

Common ColdActive, not recruiting

Atopic EczemaActive, not recruiting

UrticariaActive, not recruiting

PneumoniaActive, not recruiting

AsthmaActive, not recruiting

Common WartActive, not recruiting

Common ColdPhase 3

Active, not recruiting

Atopic EczemaPhase 2

Active, not recruiting

UrticariaPhase 2

Active, not recruiting

PneumoniaPhase 1

Active, not recruiting

AsthmaPhase 1/Phase 2

Active, not recruiting

Common WartPhase 3

Active, not recruiting

Competition

Competitive Landscape

1050 competitors in Asthma

#DrugCompanyPhaseTrials

active

Pfizer

Phase 3

2 2

Veramyst

GSK

Preclinical

46 3

Singulair

AstraZeneca

Preclinical

17 4

Nucala

GGlaxo Dba Glaxosmithkline

Preclinical

35 5

Dupixent

AAzienda U.S.L. 1 di Massa e Carrara

Preclinical

30 6

Asmanex

Novartis

Preclinical

5 7

Spiriva

Boehringer Ingelheim

Preclinical

8 8

Qvar

Chiesi Farmaceutici S.p.A.

Preclinical

8 9

Formoterol Fumarate

AstraZeneca

Preclinical

8 10

Atrovent

Boehringer Ingelheim

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Single Dose2 trials

Study Evaluating Single Doses of GAP-134

Withdrawn· Pfizer logo

Pfizer·Phase 1·NCT00820521

A Study To Investigate Safety And Pharmacokinetics Of A Single Dose Of PF-00868554 (Filibuvir) In Japanese Healthy Adult Volunteers

Completed· Pfizer logo

Pfizer·Phase 1·NCT01051232·24 enrolled

Asthma2 trials

A Study To Assess The Duration Of Action Of PF-03526299 In Asthmatic Subjects Following Allergen Challenge

Withdrawn· Pfizer logo

Pfizer·Phase 1·NCT01299467

Study to Evaluate the Bronchoprotective Effects of a Single Dose of N6022 in Patients With Mild Asthma

Completed·NNivalis Therapeutics, Inc.·Phase 1/2·NCT01316315·14 enrolled

Fungal Infection1 trial

An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Serious Fungal Infection Due To Candida In Patients With A Dysfunctional Immune System

Terminated· Pfizer logo

Pfizer·Phase 3·NCT00806351·21 enrolled

Phase 11 trial

Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH

Completed· Pfizer logo

Pfizer·Phase 1·NCT00706537·9 enrolled

Effectiveness1 trial

An Evaluation Of The Effectiveness And Safety Of Anidulafungin Compared To Caspofungin For The Treatment Of Deep Tissue Infection Due To Candida

Terminated· Pfizer logo

Pfizer·Phase 3·NCT00805740·41 enrolled

9 more indications

Nerve Block1 trial

Transversalis Fascial Plane Nerve Block in Iliac Crest Bone Graft

Completed·UUniversity Health Network, Toronto·N/A·NCT01133730·56 enrolled

Pneumonia1 trial

A Study to Learn About the Amount of the Study Medicine (Sisunatovir) in Blood and Its Safety in Infants and Children With Pneumonia Caused by RSV

Terminated· Pfizer logo

Pfizer·Phase 1·NCT06102174·10 enrolled

Immunogenicity1 trial

A Multicenter Study to Evaluate Safety and Immunogenicity of a Live-attenuated Chikungunya Vaccine in Adolescents

Completed·BButantan Institute·Phase 3·NCT04650399·750 enrolled

Common Wart1 trial

A Study of A-101 Topical Solution for the Treatment of Common Warts

Completed·AAclaris Therapeutics, Inc.·Phase 3·NCT03691831·502 enrolled

Common Cold1 trial

Efficacy and Safety of Paracetamol, Chlorpheniramine and Phenylephrine in the Treatment of Common Cold and Flu Syndrome

Completed·HHospital de Clinicas de Porto Alegre·Phase 3·NCT01389518·146 enrolled

Safety and Efficacy1 trial

A Trial to Assess the Safety and Efficacy of Topical Salbutamol in Healthy Volunteers.

Completed·UUniversity Hospitals, Leicester·Phase 1·NCT03514615·45 enrolled

Urticaria1 trial

Efficacy Study of Omalizumab in Cholinergic Urticaria

Completed·—·Phase 2·NCT02012387·24 enrolled

Atopic Eczema1 trial

Study to Investigate Skin Conditions and Patient Assessment of LAS 41002 in the Treatment of Atopic Eczema

Completed·AAlmirall, S.A.·Phase 2·NCT01119313·20 enrolled

Function1 trial

Effect of GSK962040 on Oesophageal Function

Completed· GSK logo

GSK·Phase 1·NCT01366560·14 enrolled

Sources

References

[1]
ClinicalTrials.gov — 16 trial records for active. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — active compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for active. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Pfizer

active

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Single Dose2 trials

Asthma2 trials

Fungal Infection1 trial

Phase 11 trial

Effectiveness1 trial

Nerve Block1 trial

Pneumonia1 trial

Immunogenicity1 trial

Common Wart1 trial

Common Cold1 trial

Safety and Efficacy1 trial

Urticaria1 trial

Atopic Eczema1 trial

Function1 trial

References

Drug Info

Quick Facts

Related News